Annals of medicine · 2026
Janus kinase inhibitors in the management of lichen planus: a systematic review.
Систематический обзорСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Almutairi Atheer G, Aloraini Leena I, Almutairi Abeer G, Nukaly Houriah, Khan Saleha, Shadid Asem, Alkhalifah Azzam
Аннотация
BACKGROUND AND OBJECTIVES: Lichen planus (LP) is a chronic, lymphocytic, inflammatory skin disorder that can affect the skin, hair follicles, nails, and mucous membranes. It has limited treatment options. The pathogenesis of LP includes inflammation driven by interferons and the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway. Thus, Janus kinase inhibitors (JAKi) have been proposed as a viable therapeutic approach for LP. JAKi have recently been approved to treat some lymphocytic skin disorders such as alopecia areata and atopic dermatitis. The purpose of the systematic review was to assess the effects of JAKi on LP.
MATERIALS AND METHODS: We searched PubMed, Scopus, and Google Scholar and included all studies published between January 2015 and May 2024 that assess the clinical effects of JAKi on lichen planus, including cutaneous and mucosal/adnexal variants. The risk of bias in included studies was assessed using Joanna Briggs Institute (JBI) tools, classifying bias as low, moderate and high concerns.
RESULTS: A total of 57 full-text publications were evaluated, of which 34 papers were excluded because they did not match the criteria. Therefore, this systematic review included 23 papers, seven of them were case series and the remaining 16 were case reports. There were 13 papers on tofacitinib, six on baricitinib, and two papers each on ruxolitinib and upadacitinib.
CONCLUSION: Several case series and case reports have shown beneficial effects of JAK inhibitors to treat LP. Few patients had minor adverse events.
MATERIALS AND METHODS: We searched PubMed, Scopus, and Google Scholar and included all studies published between January 2015 and May 2024 that assess the clinical effects of JAKi on lichen planus, including cutaneous and mucosal/adnexal variants. The risk of bias in included studies was assessed using Joanna Briggs Institute (JBI) tools, classifying bias as low, moderate and high concerns.
RESULTS: A total of 57 full-text publications were evaluated, of which 34 papers were excluded because they did not match the criteria. Therefore, this systematic review included 23 papers, seven of them were case series and the remaining 16 were case reports. There were 13 papers on tofacitinib, six on baricitinib, and two papers each on ruxolitinib and upadacitinib.
CONCLUSION: Several case series and case reports have shown beneficial effects of JAK inhibitors to treat LP. Few patients had minor adverse events.